Inhibikase Therapeutics
Stock Forecast, Prediction & Price Target
Inhibikase Therapeutics (IKT) stock Price Target by analysts
$6.5
Potential upside: 275.72%
Inhibikase Therapeutics price prediction
What is Inhibikase Therapeutics stock analysts` prediction?
Inhibikase Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Inhibikase Therapeutics in the last 3 months, the avarage price target is $6.5, with a high forecast of $NaN. The average price target represents a 275.72% change from the last price of $1.73.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Inhibikase Therapeutics stock Price Target by analysts
Full breakdown of analysts given Inhibikase Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Dennis Ding Jefferies | 0% 0/1 | 11 months ago | $8 362.42% upside | $2.78 | StreetInsider | Previous targets (0) |
Edward White H.C. Wainwright | 0% 0/1 | 12 months ago | $5 189.01% upside | $1.42 | TheFly | Previous targets (0) |
Inhibikase Therapeutics Financial Estimates
Inhibikase Therapeutics Revenue Estimates
Inhibikase Therapeutics EBITDA Estimates
Inhibikase Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $3.10M N/A | $123.44K -96.01% | $260.5K 111.03% | Avg: $353.84K Low: $353.84K High: $353.84K avg. 35.83% | Avg: $8.64M Low: $8.64M High: $8.64M avg. 2341.72% | Avg: $30.98M Low: $30.98M High: $30.98M avg. 258.66% | Avg: $92.55M Low: $92.55M High: $92.55M avg. 198.68% |
Net Income
% change YoY
| $-14.80M N/A | $-17.90M -20.93% | $-19.02M -6.27% | Avg: $-26.32M Low: $-7.83M High: $-7.67M avg. -38.36% | Avg: $-24.96M Low: $-7.78M High: $-4.95M avg. 5.16% | Avg: $-1.27M Low: $-1.27M High: $-1.27M avg. 94.87% | Avg: $5.11M Low: $5.11M High: $5.11M avg. 500.00% |
EBITDA
% change YoY
| $-14.76M N/A | $-18.12M -22.72% | $-19.91M -9.88% | Avg: $-353.84K Low: $-353.84K High: $-353.84K avg. 98.22% | Avg: $-8.64M Low: $-8.64M High: $-8.64M avg. -2341.72% | Avg: $-30.98M Low: $-30.98M High: $-30.98M avg. -258.66% | Avg: $-92.55M Low: $-92.55M High: $-92.55M avg. -198.68% |
EPS
% change YoY
| -$4.88 N/A | -$4.26 12.70% | -$3.57 16.19% | Avg: -$1.46 Low: -$1.47 High: -$1.44 avg. 59.24% | Avg: -$1.2 Low: -$1.46 High: -$0.93 avg. 17.86% | Avg: -$0.24 Low: -$0.24 High: -$0.24 avg. 79.91% | Avg: $0.96 Low: $0.96 High: $0.96 avg. 500% |
Operating Expenses
% change YoY
| $14.76M N/A | $18.12M 22.77% | $6.73M -62.86% | Avg: $6.02M Low: $6.02M High: $6.02M avg. -10.45% | Avg: $147.19M Low: $147.19M High: $147.19M avg. 2341.72% | Avg: $527.93M Low: $527.93M High: $527.93M avg. 258.66% | Avg: $1.57B Low: $1.57B High: $1.57B avg. 198.68% |
FAQ
What is Inhibikase Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 140.41% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -7.83M, average is -26.32M and high is -7.67M.
What is Inhibikase Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 708.72% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $353.84K, average is $353.84K and high is $353.84K.
What is Inhibikase Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 164.25% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$1.47, average is -$1.46 and high is $-1.44.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Inhibikase Therapeutics stock. The most successful analyst is Dennis Ding.